Drug Trial Radar · NCT05848687
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 3, 2023
Primary completion
Dec 2028
Study completion Dec 2033
Sponsor
- Lead sponsor
- Tanja Andrea GruberAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Pediatric Oncology Experimental Therapeutics Investigators' Consortium; Amgen; Lucile Packard Foundation for Children's Health; Kura Oncology, Inc.; United States Department of Defense; Cannonball Kid's Cancer
- First posted
- May 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Conditions
- Lymphoblastic Leukemia
Interventions
DexamethasoneDrug
Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
MitoxantroneDrug
Given IV
PEG asparaginaseDrug
Given IV
BortezomibDrug
Given IV
VorinostatDrug
Taken PO or NG
MercaptopurineDrug
Given PO or NG.
MethotrexateDrug
Given IV, IM or PO
BlinatumomabDrug
Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
ZiftomenibDrug
3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal Residual DiseaseTime frame: 5 years and 2 months
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Valley Children's Hospital
Madera, California · Recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
Rady Children's Hospital San Diego
San Diego, California · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
Children's Hospital of Minnesota
Minneapolis, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Novant Health - Hemby Children's Hospital
Charlotte, North Carolina · Not yet recruiting
Doernbecher Children's Hospital
Portland, Oregon · Recruiting
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania · Recruiting
MD Anderson
Houston, Texas · Recruiting
University of Texas Health Science Center San Antonio
San Antonio, Texas · Recruiting
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Children's Hospital of The King's Daughters
Norfolk, Virginia · Recruiting
Alberta Children's Hospital
Calgary, Alberta, Canada · Not yet recruiting
Stollery Children's Hospital
Edmonton, Alberta, Canada · Not yet recruiting
BC Children's Hospital
Vancouver, British Columbia, Canada · Not yet recruiting
McMaster Children's Hospital
Hamilton, Ontario, Canada · Not yet recruiting
CHU Sainte-Justine
Montreal, Quebec, Canada · Not yet recruiting
Montreal Children's Hospital
Montreal, Quebec, Canada · Not yet recruiting
Chu De Quebec
Québec, Quebec, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.